Recently, Amway Corporation of the United States said that it would invest in the establishment of plant research centers in China, focusing on the research and pilot planting of traditional Chinese herbal medicine. This is Amway's investment in China's R&D center in 2004, after the re-increase of R&D investment in China.

Guo Fanli, a consultant medicine industry researcher with CIC, pointed out that Amway Inc. of the United States will invest in the establishment of plant research centers in China, indicating that it is optimistic about the prospects of Chinese herbal medicine. In addition to Amway, well-known global companies like Unilever have begun to invest in Chinese herbal medicine research. The attention of multinational enterprises to Chinese herbal medicine has increased dramatically since the new health care reform. I believe that these increases are closely related to the support of the state to the Chinese herbal medicine industry in recent years.  

Developed countries abroad pay special attention to health care, green and healthy botanical medicines are particularly favored. Because of this, China's export of plant extracts has maintained a steady growth every year. However, the relevant research reports pointed out that although plant extracts account for nearly half of the export share of Chinese traditional medicine products, there are still serious homogenization and low access threshold problems in the plant extract industry in China. Therefore, China needs to establish a perfect quality standard system for plant extract industry in order to ensure the healthy and stable development of plant extract industry in China.